A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.

NCT05747729 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology